What Is Foxo4 Dri?

Visao Geral da Pesquisa

FOXO4-DRI (Proxofim) is a first-in-class senolytic peptide projetado(a) para selectively eliminate celulas senescentes — damaged, non-dividing "zombie" cells que accumulate with age and secrete harmful inflammatory factors conhecido(a) como the Senescence-Associated Secretory Phenotype (SASP). O peptideo foi desenvolvido(a) por Peter L.J. de Keizer and colleagues no(a) Erasmus University Medical Center Rotterdam and descrito(a) pela primeira vez em a landmark 2017 publication in Cell.[1]

FOXO4-DRI is derivado(a) de the Forkhead domain do(a) human FOXO4 transcricao factor — specifically a regiao que interage com p53. Its name reflects two key modificacoes estruturais: "D" denotes the use of D-aminoacidos (mirror images of natural L-aminoacidos), and "Retro-Inverso" means the aminoacido sequence is reversed. Together, these modifications produce a peptide que mimics the 3D surface do(a) original protein enquanto being highly resistant to enzymatic degradacao by proteases. O peptideo is further fused para o(a) HIV-TAT protein transduction domain to enable rapido(a) cellular uptake within 2–4 hours.[1][2]

The fundamental insight behind FOXO4-DRI is que celulas senescentes resist apoptose by upregulating FOXO4, que binds and sequesters p53 within PML nuclear bodies, preventing p53 from executing its normal pro-apoptotic functions. FOXO4-DRI acts como um(a) competitive decoy, outcompeting endogenous FOXO4 for p53 binding and liberating p53 to translocate para o(a) mitochondria and trigger caspase-dependent apoptose. Because non-celulas senescentes express minimal FOXO4 and nao depend on this survival mechanism, they are spared — achieving remarkable selectivity.[1][3]

Preclinical research demonstrou FOXO4-DRI's potencial terapeutico across a broad spectrum of age-related conditions incluindo chemotherapy-induziu toxicity, renal function decline, male hypogonadism (testosterone deficiency), vascular aging, pulmonar fibrose, osteoartrite, liver fibrose, and therapy-resistant cancers. O peptideo demonstrou restore fur density, physical activity, and kidney function in ambos(as) fast-aging and naturally camundongos idosos at a standard dose of 5 mg/kg.[1][4][5]

The biotechnology company Cleara Biotech B.V., founded by de Keizer, is advancing optimized 4th-generation variants (CL04183/CL04177) with aprimorou afinidade de ligacao and melhorou pharmacokinetic profiles toward desenvolvimento clinico. A structural milestone was reached in 2025 quando Bourgeois et al. solved the NMR structure do(a) FOXO4-DRI/p53 complex, identifying the p53 Transativacao Domain 2 (TAD2) como o(a) specific binding site and demonstrating que p53 fosforilacao at Ser46 and Thr55 aprimora afinidade de ligacao.[2][3]